+34 620 10 75 37info@nanbiosis.com

Nanbiosis

NANBIOSIS Unit 6 Delivers Training on Particle Characterisation Techniques

NANBIOSIS Unit 6 delivered a hands-on training course on particle characterisation techniques, covering DLS, NTA and light scattering.

Barcelona, October 2026 — From 5 to 7 October 2026, José Amable Bernabé delivered a 21-hour training course on Particle Characterisation Techniques in Bellaterra (Barcelona), highlighting the analytical capabilities available through NANBIOSIS Unit 6.

The course was organised by the Deputy General Secretariat for Human Resources in collaboration with the Institute of Materials Science of Barcelona (ICMAB-CSIC). It was aimed at scientific personnel seeking to develop practical knowledge of techniques used to characterise particulate materials, particularly researchers and staff working at ICMAB.

The programme combined theoretical sessions with hands-on training, introducing participants to three key analytical techniques:

  • Dynamic Light Scattering (DLS): particle size distribution and zeta potential measurements.
  • Nanoparticle Tracking Analysis (NTA): particle size distribution, particle concentration measurements and fluorescence-based analysis.
  • Light Scattering (LS): particle size distribution measurements.

Practical sessions provided participants with the opportunity to analyse samples and interpret experimental results using three analytical instruments: the Zetasizer Nano ZS for DLS, the NanoSight NS300 for NTA and the Mastersizer 2000 for light scattering.

Throughout the course, the connection between these analytical services and NANBIOSIS Unit 6 was highlighted, showcasing the infrastructure’s capabilities in particle characterisation and its contribution to supporting research in materials science and nanotechnology.

Through specialised training and access to advanced analytical equipment, NANBIOSIS continues to support the scientific community in developing and applying techniques essential for the characterisation of advanced materials and nanomaterials.

NANBIOSIS Unit 6: Advanced materials for health

The poster highlights the mission of NANBIOSIS Unit 6, located at ICMAB-CSIC and coordinated by Prof. Nora Ventosa. This Unit specializes in the development, characterisation, and scale-up of molecular biomaterials with applications in biomedicine.

Equipped with state-of-the-art facilities and operating under ISO 9001 quality standards, Unit 6 offers advanced technologies such as the DELOS-SUSP method, a compressed-fluid-based process for producing highly controlled micro- and nanostructured materials. Its unique capability to scale processes from laboratory to industrial levels supports both research and technology transfer.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS Joins the V Annual Conference of Spain’s Singular Scientific and Technical Infrastructures in Zaragoza

NANBIOSIS took part in the 2026 ICTS Conference in Zaragoza, bringing together Spain’s leading scientific infrastructures to exchange knowledge and explore collaboration opportunities.

Zaragoza, October 2026 — Last 29 October 2026, the V Annual Conference of Spain’s Singular Scientific and Technical Infrastructures (ICTS) took place in Zaragoza, bringing together representatives from across the Spanish ICTS network. The event provided a forum to share developments, strengthen collaboration between infrastructures and showcase their scientific and technological capabilities to the research and industrial communities.

This year’s conference was hosted by the Laboratory of Advanced Microscopy (LMA) and the Institute for Biocomputation and Physics of Complex Systems (BIFI), both at the University of Zaragoza. Sessions were held at the Agustín de Betancourt Building, home to the University’s School of Engineering and Architecture (EINA).

The programme included two round tables addressing key challenges for research infrastructures: artificial intelligence in ICTS and data management plans (DMPs). These discussions provided an opportunity to exchange perspectives on the role of emerging technologies and effective data management in the development and operation of large-scale scientific facilities.

Participants also had the opportunity to visit the LMA facilities and the Aragonese node of the Spanish Supercomputing Network (RES), alongside the conference’s networking activities.

The event scenified a minute of silence in memory of the victims of the Urda train accident. In addition, participants who were unable to attend in person were offered the possibility of joining the sessions by videoconference.

Through its participation, NANBIOSIS reaffirmed its commitment to the Spanish ICTS network, contributing to a shared effort to promote scientific excellence, facilitate access to advanced research infrastructures and foster collaboration across the national research and innovation ecosystem.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS Promotes Nanomedicine Through an Educational Game at Science Outreach Events in Barcelona

NANBIOSIS Unit 20 promotes nanomedicine through an interactive educational game presented at several science outreach events in Barcelona.

Barcelona, October 2026 — NANBIOSIS is supporting science communication and public engagement through an educational game developed by its Unit 20 (FVPR), designed to introduce audiences to the fascinating world of nanomedicine and nanoparticle-based technologies.

Entitled “Missió nanoagent: El viatge d’una nanopartícula” (Nano-Agent Mission: The Journey of a Nanoparticle), this boardgame invites participants to explore the journey of a nanoparticle, helping them discover scientific concepts related to nanotechnology and its biomedical applications. The initiative also features the NANBIOSIS logo, raising awareness of the infrastructure and its research capabilities among the general public.

The game has been presented at several science outreach activities in Barcelona, including the Festa de la Ciència at the Centre de Cultura Contemporània de Barcelona (CCB) in April, and the European Researchers’ Night at CosmoCaixa, where it was featured in a session on Friday, 28 September. It was also showcased on 3 October at the Vall d’Hebron Research Institute (VHIR), as part of the 48h Open House Barcelona programme.

NANBIOSIS was also highlighted during the European Researchers’ Night through the talk “¡Hasta el cerebro! La increíble ruta de las nanopartículas” (All the Way to the Brain! The Incredible Journey of Nanoparticles), delivered by Fernanda Andrade at CosmoCaixa. The presentation featured the NANBIOSIS logo and discussed in vivo research results obtained through a service provided by the infrastructure.

Through initiatives like these, NANBIOSIS Units contribute not only to biomedical research and technological development but also to bringing science closer to society, making complex topics such as nanomedicine more accessible and engaging for different audiences.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Mesoporous Nanoparticles: Properties, Synthesis and Biomedical Applications

Introduction

Mesoporous nanoparticles are nanostructured materials containing pores with diameters typically between 2 and 50 nanometres. Their combination of nanoscale dimensions and an internal porous architecture gives them properties that are particularly attractive for biomedical research, including a high specific surface area, substantial pore volume and the possibility of modifying both their internal pores and external surface.

Among the different types of mesoporous nanoparticles, mesoporous silica nanoparticles (MSNs) are among the most extensively investigated for biomedical applications. Their silica framework can be engineered to control particle size, pore size, morphology and surface chemistry. These characteristics have made MSNs promising platforms for the delivery of drugs, proteins and nucleic acids, as well as for bioimaging, biosensing and tissue engineering.

Importantly, mesoporous nanoparticles are a research platform rather than a single material. Depending on their composition and design, they can include silica-based, carbon-based, polymeric and other inorganic mesoporous systems. Their properties and biological behaviour therefore depend strongly on their composition, size, morphology, surface chemistry and method of preparation.

What are mesoporous nanoparticles?

The term mesoporous refers primarily to the size of the pores within a material. According to the conventional classification of porous materials, pores are generally described as:

  • Micropores: smaller than 2 nm
  • Mesopores: 2–50 nm
  • Macropores: larger than 50 nm

Mesoporous nanoparticles combine this porous structure with nanoscale particle dimensions. In the case of MSNs, the particle consists principally of a silica (SiO₂) framework containing an ordered or partially ordered network of mesopores.

The pores can provide internal space for loading molecules, while the outer surface can be chemically modified with functional groups, polymers, peptides, targeting ligands or other components. This separation between the internal cargo-loading space and the external surface is one of the characteristics that makes mesoporous nanoparticles particularly versatile.

The pore size, pore volume, particle size, morphology and surface charge can be adjusted during synthesis. These parameters influence how molecules interact with the nanoparticles, how much cargo can be loaded and how the particles interact with biological systems.

For biomedical applications, mesoporous silica nanoparticles are particularly attractive because silica chemistry allows relatively straightforward surface functionalization. However, the term mesoporous nanoparticles should not be considered synonymous with mesoporous silica nanoparticles: MSNs are one important subgroup within the broader family.

Advantages of mesoporous nanoparticles

Mesoporous nanoparticles offer several characteristics that can be useful when designing biomedical nanomaterials.

High specific surface area

The presence of numerous nanoscale pores can provide a large internal and external surface area relative to the particle’s overall size. This can facilitate the adsorption or loading of therapeutic and diagnostic molecules.

High and tunable loading capacity

The porous architecture provides internal volume that can accommodate a range of molecules. Depending on the material and surface chemistry, mesoporous nanoparticles have been investigated for loading small-molecule drugs as well as larger biological cargoes such as proteins, DNA and RNA.

Controlled and stimuli-responsive release

The release of molecules from mesoporous nanoparticles can be influenced by pore characteristics and surface modifications. Researchers have developed systems designed to respond to conditions such as pH, enzymes, redox conditions, temperature, light or magnetic fields, with the aim of controlling when and where a cargo is released.

Versatile surface functionalization

Silica surfaces can be chemically modified with different functional groups. This enables the incorporation of polymers, targeting molecules, biomolecules and other components designed to modify cellular interactions, colloidal behaviour or cargo release.

Structural tunability

Particle size, morphology, pore diameter and surface properties can be adjusted through changes in synthesis conditions. This tunability allows researchers to design mesoporous nanoparticles for different experimental requirements.

These advantages do not automatically translate into clinical efficacy or safety. Biodistribution, degradation, clearance, biological interactions and toxicity must be evaluated for each specific formulation and application. Current research continues to address these issues and the challenges involved in clinical translation.

How are mesoporous nanoparticles synthesized?

The synthesis method depends on the composition and intended characteristics of the nanoparticles. For mesoporous silica nanoparticles, one of the most widely used approaches is template-directed sol-gel synthesis.

In a typical process, a silica precursor such as tetraethyl orthosilicate (TEOS) is combined with a structure-directing agent, often a surfactant. The surfactant molecules self-assemble into micellar or other organized structures. Silica precursors undergo hydrolysis and condensation around these structures, generating the silica framework. Subsequent removal of the template leaves behind the mesoporous network.

Different synthesis strategies can be used to control the resulting particle characteristics. These include:

  • Sol-gel and soft-templating approaches, widely used for MSNs.
  • Hard-templating methods, in which a pre-existing structure is used to define the resulting porous architecture.
  • Hydrothermal approaches, which can modify particle formation and mesostructure.
  • Modified Stöber-type methods and related colloidal synthesis strategies.
  • Alternative and more sustainable synthesis approaches, including some biomimetic and green synthesis methods.

Parameters such as precursor concentration, surfactant type and concentration, pH, temperature, reaction time and the ratio between the different components can influence particle size, morphology and pore structure. Consequently, synthesis is an important part of designing a mesoporous nanoparticle for a particular biomedical application.

After synthesis, additional steps may be required to remove the template, purify the nanoparticles and functionalize their surfaces. Surface engineering can subsequently be used to modify properties such as charge, targeting behaviour, colloidal stability or responsiveness to specific biological conditions.

Biomedical applications of mesoporous nanoparticles

The combination of a tunable porous structure, large surface area and modifiable surface chemistry has led to extensive investigation of mesoporous nanoparticles in biomedicine. Key areas include biomolecule and gene delivery, regenerative medicine, diagnostic imaging and drug delivery.

1. Biomolecule delivery and gene therapy

One of the most actively investigated applications of mesoporous nanoparticles is the delivery of biological macromolecules and nucleic acids.

The pores of mesoporous nanoparticles can provide space for loading proteins, peptides, antigens and nucleic acids, while surface functionalization can be used to influence interactions with cells and biological barriers. MSNs have therefore been investigated as carriers for DNA, RNA and other therapeutic biomolecules.

Gene delivery presents particular challenges because nucleic acids are susceptible to degradation and their successful therapeutic use generally requires protection, cellular uptake and appropriate intracellular trafficking. Mesoporous silica nanoparticles can be functionalized with positively charged groups, polymers, peptides or other components to facilitate nucleic-acid association and cellular delivery.

Research has explored MSN-based systems for the delivery of plasmid DNA, small interfering RNA (siRNA), messenger RNA and other nucleic-acid cargos. More recently, mesoporous silica platforms have also been investigated for delivering components associated with CRISPR-based gene editing.

An important research objective is to control the entire delivery process, from protection of the cargo and cellular uptake to intracellular release. Surface engineering and core-shell architectures are among the strategies being investigated to overcome biological barriers and improve delivery efficiency.

It is important to distinguish these research developments from established clinical applications. Although mesoporous nanoparticles have demonstrated considerable potential in experimental gene and biomolecule delivery, further work is required to address issues such as biodistribution, biodegradation, toxicity, immune interactions and efficient delivery in vivo.

2. Regenerative medicine

Mesoporous silica nanoparticles have also been investigated in tissue engineering and regenerative medicine.

Their porous structure and modifiable surface chemistry can enable them to act as carriers for bioactive molecules within biomaterial systems. For example, MSNs can be incorporated into scaffolds or other engineered materials with the objective of providing localized and controlled delivery of biological signals.

In tissue engineering, this approach can be particularly interesting when the spatial and temporal presentation of bioactive molecules is important. Mesoporous nanoparticles can potentially provide a reservoir for molecules that would otherwise diffuse rapidly from a biomaterial.

Research has investigated MSN-containing systems in areas including bone regeneration, tissue engineering and bioactive scaffolds. The nanoparticles can also be combined with other biomaterials to create multifunctional systems whose mechanical, structural and biological properties are tailored to a particular application.

As with other biomedical uses, these approaches remain an active area of research, and factors such as nanoparticle degradation, long-term biological effects and interactions with the surrounding tissue need to be carefully evaluated.

3. Diagnostic imaging

Mesoporous nanoparticles can also serve as components of biomedical imaging and theranostic platforms.

Their porous structure provides space for incorporating imaging-related components, while their surfaces can be functionalized with molecules designed to interact with specific biological targets. MSNs have been investigated in combination with fluorescent materials, magnetic nanoparticles and other imaging agents to develop multifunctional systems.

This approach can enable the combination of imaging and therapeutic functions in a single nanoplatform. Such systems are commonly described as theranostic nanoparticles, particularly when diagnostic information is integrated with therapeutic delivery.

Mesoporous materials have also been investigated in biosensing and in vitro diagnostic applications. Their high surface area and capacity for surface functionalization can be useful for immobilizing recognition molecules and signal-generating components.

4. Drug delivery

Drug delivery remains one of the most extensively studied biomedical applications of mesoporous nanoparticles.

The internal pore network can accommodate therapeutic compounds, including molecules with poor aqueous solubility. Surface modifications and pore-gating strategies can then be used to influence drug release. Research has explored systems designed for immediate, sustained, controlled, targeted and stimuli-responsive drug delivery.

Stimuli-responsive systems are particularly interesting because they are designed to release their cargo in response to specific environmental conditions. Depending on the system, the trigger may be a change in pH, redox state, enzyme activity, temperature, light or another physical or chemical stimulus.

Mesoporous nanoparticles have therefore been investigated for the delivery of a wide variety of therapeutic compounds, including anticancer agents and poorly soluble drugs. However, the development of an effective nanomedicine requires more than high drug loading: stability, pharmacokinetics, biodistribution, toxicity, clearance and reproducible manufacturing must also be considered.

Frequently Asked Questions

What are mesoporous nanoparticles?

Mesoporous nanoparticles are nanoscale particles containing pores generally measuring between 2 and 50 nm in diameter. Their porous structure provides a high surface area and internal volume that can be exploited for molecular loading and other biomedical applications.

What are mesoporous silica nanoparticles?

Mesoporous silica nanoparticles (MSNs) are a type of mesoporous nanoparticle in which the porous framework is primarily composed of silica. They are extensively studied because their particle size, pore structure and surface chemistry can be engineered for different applications.

What can mesoporous nanoparticles be used for?

Research applications include biomolecule and gene delivery, regenerative medicine, drug delivery, diagnostic imaging, biosensing and theranostics.

Can mesoporous nanoparticles deliver DNA and RNA?

Yes. Mesoporous silica nanoparticles have been investigated for the delivery of different nucleic acids, including DNA and RNA. Surface functionalization can help address challenges associated with nucleic-acid loading, cellular uptake and intracellular delivery.

Why are mesoporous nanoparticles useful for drug delivery?

Their internal pores provide space for loading therapeutic compounds, while their surface chemistry can be modified to influence interactions with biological systems and drug release. Some systems can also be engineered to respond to specific environmental stimuli.

Are mesoporous nanoparticles safe?

Safety depends on the specific nanoparticle, including its composition, size, morphology, surface chemistry, dose and route of administration. Although many mesoporous nanoparticle systems have shown promising biocompatibility in experimental studies, biosafety, biodistribution, degradation and long-term biological effects remain important areas of research.

Are mesoporous nanoparticles clinically approved?

Mesoporous nanoparticles are primarily an active research area in nanomedicine. Promising experimental results do not by themselves establish clinical efficacy or regulatory approval, and translation requires extensive evaluation of safety, manufacturing, pharmacology and clinical performance.

Conclusion

The design and characterization of mesoporous nanoparticles often requires expertise spanning nanomaterial synthesis, physicochemical characterization, biomolecule loading, in vitro testing, imaging and preclinical evaluation.

Through its distributed infrastructure, NANBIOSIS provides access to complementary capabilities for the development and characterization of nanomedicine technologies, supporting research projects from material design and characterization through biological evaluation and preclinical research.

Related articles

  • …

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS launches an integrated service for recombinant antigen and antibody development

NANBIOSIS combines recombinant antigen design, custom antibody production and proteomics to tackle challenging biomedical targets.

Barcelona and A Coruña, October 2026 — Developing antibodies against specialised or emerging biomedical targets can be challenging when the corresponding proteins are difficult to produce, unstable, poorly soluble or lack suitable exposed epitopes. NANBIOSIS now brings together complementary expertise in recombinant protein production, custom antibody development and proteomic analysis to address these challenges through a single coordinated workflow.

The service combines the capabilities of NANBIOSIS Unit 1 (Protein Production Platform), Unit 2 (Custom Antibody Service, CAbS) and Unit 30 (Proteomics).

The workflow begins with the design and production of tailored recombinant proteins or specialised chimeric constructs. Unit 1 can optimise antigenic domains and protein production strategies according to the characteristics of the target, followed by protein purification.

These custom-engineered antigens can then be directly used by Unit 2 for polyclonal or monoclonal antibody development. The service covers the main stages of antibody generation, from immunogen preparation and immunisation through screening, selection and antibody purification.

Where required, Unit 30 provides complementary mass spectrometry-based proteomic analysis to confirm the identity and integrity of the proteins or antibodies generated. Proteomic analysis can also support the identification of post-translational modifications, sequence variants and mutations.

An integrated approach for challenging targets

By connecting antigen engineering with downstream antibody development, the service offers researchers and companies an integrated route from target design to validated antibody reagents. This can be particularly valuable when commercially available antigens are unavailable or when conventional antibody-development strategies are unsuitable for a specific target.

The combined workflow can help address challenges such as protein instability, poor solubility and cross-reactivity, while enabling the development of bespoke reagents adapted to specific research and diagnostic applications.

Experience in SARS-CoV-2 antigen and antibody development

The capabilities behind this service have already been applied in collaborative projects. During the COVID-19 pandemic, Unit 1 and Unit 2 worked together on the development of recombinant SARS-CoV-2 Spike S1 antigens and anti-S1 antibodies.

Within the POC4CoV project, CAbS contributed to the development of antibodies against the SARS-CoV-2 Spike protein and other viral proteins for potential use in diagnostic technologies. The team also generated and purified an in-house rabbit polyclonal antibody against recombinant Spike S1, subsequently used as a positive and quality-control reagent in the development and manufacturing of the Immuno-μSARS2 peptide/protein microarray.

The resulting work was reported in ACS Pharmacology & Translational Science in 2025 in the publication “Immuno-μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints.”

From bespoke antigen design to antibody development

By bringing together protein engineering, antibody production and proteomic expertise, NANBIOSIS provides a coordinated solution for researchers and companies seeking custom antibodies against difficult or specialised targets.

From bespoke recombinant antigens to high-affinity antibodies: one integrated pipeline for targets standard methods can’t reach.

Request a NANBIOSIS service here.

Want to stay up to date?

Our newsletter, sent every three months, is what you need. We do not spam. Subscribe here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS researcher presents polymeric nanoparticle research at RANN XIV

NANBIOSIS researcher Santiago Grijalvo presented new polymeric nanoparticle strategies for nucleic acid and phytochemical delivery at RANN XIV.

Barcelona, August 2026 — Santiago Grijalvo, researcher at NANBIOSIS Unit U12, presented an oral communication at the XIV Meeting on Nucleic Acids and Nucleosides (RANN XIV), held in Barcelona on 29 August 2026.

His presentation, “A Modular PLGA Nanoplatform Integrating Antisense Oligonucleotide Delivery and Antioxidant Co-Therapy,” highlighted recent research into polymeric nanoparticles as delivery vehicles for nucleic acids and phytochemicals. The work explores the potential of these nanoplatforms to combine different therapeutic components and improve their delivery, supporting the development of advanced nanomedicine strategies.

The research was conducted in collaboration with CIBER-BBN and CIBER-NED, bringing together expertise from different fields to investigate innovative approaches for therapeutic delivery.

NANBIOSIS expertise in nucleic acid delivery

The participation of NANBIOSIS researchers at RANN XIV reflects the infrastructure’s involvement in research addressing challenges in nanomedicine, nucleic acid delivery and advanced therapeutic technologies.

The meeting brought together young researchers and experienced experts working across nucleic acid and nucleoside chemistry and biology, including structural studies, advanced therapies, molecular modelling, bioinformatics and synthetic methodologies. RANN XIV was held at the Hotel Barceló Sants in Barcelona and was organised alongside the International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026).

NANBIOSIS was also represented among the event organisers. Prof. Ramon Eritja, Scientific Director of NANBIOSIS Unit 29, and Dr. Anna Aviñó, Scientific Coordinator of Unit 29, were members of the RANN XIV and IRT 2026 Organising Committee.

Through its multidisciplinary capabilities, NANBIOSIS supports research and development in drug delivery, nucleic acids, nanomaterials and nanomedicine, helping researchers and companies advance innovative biomedical solutions from development towards preclinical applications.

Want to stay up to date?

Our newsletter, sent every three months, is what you need. We do not spam. Subscribe here.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Development of an injectable hydrogel for local and sustained chemotherapy delivery

A natural injectable hydrogel developed at VHIR enables sustained local docetaxel delivery and shows antitumor activity in preclinical cancer models.

Barcelona, September 2026 — Researchers at the Vall d’Hebron Research Institute (VHIR) have developed an injectable hydrogel made from natural polymers that enables local and sustained delivery of chemotherapy. The system, based on cellulose and chitosan, has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The results, published in Carbohydrate Polymer Technologies and Applications, describe a soft and injectable hydrogel designed to act as a local depot for chemotherapy. The researchers incorporated docetaxel into polymeric micelles approximately 72 nm in diameter and subsequently integrated these micelles into the hydrogel. The resulting system released approximately 70% of the drug over 14 days while maintaining its structure for more than three weeks under physiological conditions.

From computational modelling to preclinical validation

The formulation was optimized using molecular simulations and computational modelling (in silico) to study interactions between its different components. Experimental characterization showed that the hydrogel has thixotropic behaviour, becoming more fluid during injection and recovering its structure afterwards. Studies in mice also confirmed its injectability and ability to remain localized at the administration site.

The researchers further evaluated the system in biological models. Tests in healthy fibroblasts showed high biocompatibility, while studies using ovarian cancer and glioblastoma cell models demonstrated sustained cytotoxic activity. In three-dimensional glioblastoma models, the micelles released from the hydrogel were able to penetrate the tumour spheroids and maintain their activity over time.

A potential platform for local cancer treatment

Local and sustained drug delivery could help maintain drug exposure at the target site while potentially limiting systemic exposure. However, the researchers emphasize that the current results are preclinical, and further studies will be required before the technology could be considered for clinical application.

The study involved CIBER-BBN and the Functional Validation and Preclinical Research Platform (U20) of NANBIOSIS, together with the University of Barcelona, the Universitat Autònoma de Barcelona and international research centres. The work brings together computational modelling, nanotechnology, biomaterials and advanced biological validation to explore new approaches for the local treatment of solid tumours.

This work illustrates the capabilities available through NANBIOSIS U20, which contributes expertise in functional validation and preclinical research to the development and evaluation of advanced biomedical technologies.

More information can be found in the website of VHIR.

Reference: Naturally-derived cellulose-chitosan soft-hydrogel for sustained local docetaxel micelles delivery: from in silico modeling to preclinical validation in ovarian and glioblastoma models

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

NANBIOSIS Presented at ESB 2026 in Antwerp

NANBIOSIS was presented at ESB 2026 in Antwerp, highlighting its role in connecting academia and industry in biomedical research.

Antwerp, September 2026 — NANBIOSIS participated in the 35th Annual Conference of the European Society for Biomaterials (ESB 2026), held from 7 to 11 September 2026 in Antwerp, Belgium, marking the 50th anniversary of the European Society for Biomaterials.

Representing NANBIOSIS, Gabriel Alfranca, Internationalization and Communication Manager, presented a poster introducing the infrastructure and its role in supporting biomedical research and development. The poster, listed as D2-P031, was titled “NANBIOSIS: A distributed research infrastructure bridging Academia and Industry up to preclinical development.”

The conference brought together scientists, clinicians, engineers, industry representatives and students working across the biomaterials field. Its scientific programme covered areas including tissue engineering, regenerative medicine, biofabrication, drug delivery, medical devices, biomaterials, advanced manufacturing and clinical translation.

ESB 2026 provided an opportunity for NANBIOSIS to increase its visibility within the international biomaterials and biomedical research community and to introduce its capabilities to researchers and professionals interested in translating innovative technologies towards preclinical development.

Through its participation in international scientific events such as ESB 2026, NANBIOSIS continues to promote collaboration and awareness of its distributed research infrastructure among academic and industrial communities.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

If you want to collaborate with us, visit our Order Request page.

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

TODAY: NANBIOSIS to Participate in CIBEROBN Webinar on Translational Biomedicine

NANBIOSIS will participate online this afternoon, September 17, 2026, at 4:00 p.m., in the CIBEROBN Webinars 2026 session “Translational Biomedicine: Disease Mechanisms and Advanced Research Infrastructures.” The webinar is part of the programme organised by the Spanish Biomedical Research Network (CIBEROBN).

The session will focus on “Intestinal proteases in the spotlight: drivers of alcohol-associated liver disease progression”, addressing current research into disease mechanisms and translational biomedicine.

The webinar will also feature an introduction to NANBIOSIS, presented by Gabriel Alfranca, Communication and Internationalization Manager of CIBER-BBN and NANBIOSIS. The presentation will introduce NANBIOSIS as an advanced biomedical research infrastructure supporting research and innovation in areas including nanomedicine, biomaterials and bioengineering.

The event will provide an opportunity to present NANBIOSIS to researchers and other professionals interested in translational biomedical research and advanced research infrastructures.

Date: September 17, 2026
Time: 4:00 p.m.
Format: Online
Programme: CIBEROBN Webinars 2026

JOIN THE WEBINAR HERE

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More

Polymeric Nanoparticles: Properties, Synthesis and Biomedical Applications

Introduction

Polymeric nanoparticles are among the most versatile platforms being investigated in nanomedicine. Their ability to encapsulate, protect and transport different types of therapeutic or diagnostic cargo makes them attractive for applications ranging from drug delivery and gene therapy to medical imaging, cancer research and biosensing.

Unlike many conventional drug-delivery systems, polymeric nanoparticles can be engineered by modifying their polymer composition, size, surface properties and internal structure. This allows researchers to tailor their behaviour to a particular biological application, including controlling how a nanoparticle interacts with cells, how long it remains in circulation and how its cargo is released.

The field has advanced considerably through the development of biodegradable polymers, surface functionalization strategies and stimuli-responsive materials. However, most polymeric nanoparticle technologies remain at the research or development stage, and important challenges related to safety, biodistribution, reproducibility, manufacturing and clinical translation still need to be addressed.

What are polymeric nanoparticles?

Polymeric nanoparticles (PNPs) are nanoscale particles formed from polymeric materials. In biomedical research, they are generally designed as carriers or functional nanomaterials whose physicochemical properties can be controlled through the choice of polymer, formulation and surface chemistry.

Depending on their composition and preparation method, polymeric nanoparticles can contain a therapeutic or diagnostic molecule within the particle, associated with the polymer matrix or attached to its surface. Both natural and synthetic polymers have been investigated for these applications.

Examples of polymers used in polymeric nanoparticle systems include poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid (PLA), polycaprolactone (PCL), chitosan and various functional synthetic polymers. PLGA is particularly widely studied because it is biodegradable and has a long history of investigation in biomedical applications.

The physicochemical characteristics of a polymeric nanoparticle—including particle size, size distribution, morphology, surface charge, polymer composition and surface functionalization—can strongly influence its biological behaviour. These parameters can affect colloidal stability, cellular uptake, biodistribution and cargo release.

Importantly, polymeric nanoparticles are not a single type of nanomaterial. Different architectures and formulations can be designed for different purposes, making them a broad platform rather than one standardized technology.

Advantages of polymeric nanoparticles

One of the main advantages of polymeric nanoparticles is their design flexibility. Polymer chemistry allows researchers to modify the structure and properties of the particles according to the intended application.

Controlled and sustained release

Polymeric matrices can be designed to control the release of an encapsulated compound. Depending on the polymer and formulation, release can occur through mechanisms such as diffusion, polymer degradation or changes in the surrounding environment.

This can potentially provide a more controlled exposure to a therapeutic compound than conventional formulations.

Protection of sensitive biomolecules

Nanoparticles can help protect certain biological molecules from degradation before they reach their intended site of action. This is particularly relevant for proteins, peptides and nucleic acids, which can be vulnerable to enzymatic degradation or other biological barriers.

Tunable surface properties

The surface of polymeric nanoparticles can be modified with different chemical groups or biomolecules. Such functionalization can alter interactions with biological systems and, in experimental systems, can be used to investigate strategies for targeting particular cells or tissues.

Versatility in cargo

Polymeric nanoparticles have been investigated for the delivery of a wide variety of molecules, including small-molecule drugs, proteins, peptides, DNA, RNA and other biomolecules.

Biodegradability

Some polymers used in biomedical nanoparticles are biodegradable. For example, PLGA can undergo hydrolytic degradation into lactic acid and glycolic acid, which are subsequently metabolized by the body. However, biodegradability and biocompatibility depend on the specific material, formulation and application and should not be assumed for every polymeric nanoparticle.

How are polymeric nanoparticles synthesized?

The synthesis of polymeric nanoparticles involves producing particles with controlled size, composition and surface characteristics while incorporating the desired cargo.

Several approaches are used, and the appropriate method depends on the polymer, cargo and intended application.

Nanoprecipitation

Nanoprecipitation, also known as solvent displacement, is a widely used approach. A polymer is dissolved in a suitable organic solvent and introduced into a second phase, commonly under controlled mixing conditions. Changes in solvent conditions promote polymer aggregation and nanoparticle formation.

The method can be relatively straightforward and is particularly useful for incorporating hydrophobic compounds.

Emulsification and solvent evaporation

In emulsion-based methods, a polymer solution and another immiscible phase are combined to form droplets. The solvent is subsequently removed, leaving polymeric nanoparticles.

Different configurations, including single and double emulsions, can be used depending on the properties of the cargo. Double-emulsion methods are particularly relevant for incorporating hydrophilic biomolecules such as proteins into polymeric particles.

Polymerization-based methods

Nanoparticles can also be generated directly through polymerization reactions. Examples include emulsion polymerization and related approaches in which monomers are converted into polymeric particles under controlled reaction conditions.

Self-assembly

Some polymers are designed to self-assemble in solution because different parts of the polymer interact differently with the surrounding environment. This approach can produce nanoscale structures with defined architectures and is particularly relevant for amphiphilic polymers.

The synthesis method affects important properties such as particle size, morphology, surface characteristics, encapsulation efficiency and release behaviour. Consequently, formulation and process parameters must be carefully controlled and characterized when developing a biomedical nanoparticle system.

Biomedical applications of polymeric nanoparticles

Polymeric nanoparticles are being investigated across a broad range of biomedical applications. Their ability to combine nanoscale dimensions with programmable polymer chemistry makes them particularly interesting for applications in which the delivery, protection or localization of a biological molecule is important.

1. Delivery of biomolecules and gene therapy

One of the most important research areas for polymeric nanoparticles is the delivery of biomolecules and genetic material.

Nucleic acids such as DNA, messenger RNA (mRNA), small interfering RNA (siRNA) and other oligonucleotides present particular delivery challenges. They are generally large or negatively charged molecules and can be degraded before reaching their intracellular target.

Polymeric systems can be engineered to interact with nucleic acids and facilitate their transport across biological barriers. Cationic polymers, for example, can form complexes with negatively charged nucleic acids, producing structures known as polyplexes. Other polymeric nanoparticles can encapsulate or otherwise associate with nucleic acids and release them after cellular uptake.

Research in this area focuses on overcoming several barriers, including circulation in the body, cellular uptake, endosomal escape and intracellular release. Surface modification and stimulus-responsive polymer designs are among the strategies being investigated to improve delivery.

Polymeric nanoparticles are therefore being explored as platforms for gene therapy, RNA delivery and other nucleic-acid-based therapeutics. However, successful delivery in experimental models does not necessarily translate directly into clinical efficacy, and the field continues to face challenges involving toxicity, biodistribution, immune responses and efficient intracellular delivery.

2. Diagnostic imaging

Polymeric nanoparticles can also be engineered to carry or present imaging agents, creating nanoscale platforms for biomedical imaging and, in some cases, theranostic applications.

A polymeric nanoparticle can potentially combine an imaging component with targeting or therapeutic functionality. By modifying the particle surface, researchers can investigate strategies to influence interactions with specific cells or tissues.

Research has explored polymeric nanoparticles in cancer imaging and other diagnostic applications, although the suitability of a particular nanoparticle depends strongly on the imaging modality and the properties of the incorporated contrast or imaging agent.

3. Drug delivery

Drug delivery remains one of the most extensively investigated applications of polymeric nanoparticles.

A nanoparticle can encapsulate or associate with a drug and modify its physicochemical and pharmacokinetic behaviour. This can be particularly useful for compounds with poor aqueous solubility, limited stability or undesirable systemic distribution.

Polymeric nanoparticles have been investigated for controlled delivery through several administration routes, including intravenous, oral, nasal, topical and ocular administration. Their potential advantages include protection of the cargo, controlled release and the possibility of modifying interactions with biological barriers.

In oncology, for example, polymeric nanoparticles are being investigated to improve the delivery of anticancer compounds and to explore strategies for increasing drug concentration at tumour sites while reducing exposure to healthy tissues.

4. Nanomedicine and catalysis in the tumour environment

The tumour microenvironment presents a complex combination of biological and physicochemical conditions, including variations in pH, oxygen availability, enzymes and redox state.

These characteristics have motivated the development of stimuli-responsive polymeric nanoparticles designed to change their behaviour in response to particular environmental conditions.

Researchers are investigating polymeric nanoparticles that can respond to factors such as pH, temperature, enzymes or redox conditions, potentially enabling more localized release or activation of a therapeutic payload. Such approaches are part of the broader development of multifunctional nanomedicine and theranostic systems.

Polymeric nanoparticles can also serve as platforms for incorporating catalytic components. In experimental nanomedicine, this includes approaches designed to modify biochemical reactions within disease-associated microenvironments. These technologies remain an active research area and should not be interpreted as established clinical treatments.

5. Sensors

The large surface area and chemically tunable interfaces of nanoparticles make them attractive for biosensing and sensor technologies.

Polymeric nanoparticles can be functionalized with recognition molecules or other components that interact with a target analyte. Changes in the nanoparticle or its associated sensing system can then be translated into a measurable signal.

Applications under investigation include the detection of biological molecules, pathogens and disease-related biomarkers. Polymer-based nanoparticle systems have also been studied as components of broader nanosensor platforms.

6. Artificial enzymes

Another emerging research direction involves artificial enzymes, sometimes referred to as nanozymes when nanomaterials exhibit enzyme-like catalytic activity.

Polymeric nanostructures can be engineered as catalytic platforms or combined with catalytic components to create systems capable of performing specific chemical reactions. In biomedical research, these systems are being investigated for applications such as sensing, therapeutic catalysis and modulation of biochemical environments.

This is a developing field, and the properties and mechanisms of artificial enzyme systems vary substantially between formulations. Their potential should therefore be considered primarily in the context of ongoing research rather than established clinical applications.

Frequently Asked Questions

What are polymeric nanoparticles used for?

Polymeric nanoparticles are investigated for drug delivery, gene and biomolecule delivery, diagnostic imaging, biosensing, cancer nanomedicine and other biomedical applications. Their main advantage is the ability to engineer their composition and surface properties for specific purposes.

Are polymeric nanoparticles biodegradable?

Some polymeric nanoparticles are made from biodegradable polymers, such as PLGA, PLA or PCL. However, not all polymers are biodegradable, and biodegradation depends on the specific polymer, formulation and biological environment.

How are polymeric nanoparticles made?

Common methods include nanoprecipitation, emulsification and solvent evaporation, polymerization-based techniques and self-assembly. The selected method depends on the polymer and the type of cargo that needs to be incorporated.

Can polymeric nanoparticles deliver DNA or RNA?

Yes. Polymeric nanoparticles and polymer-based complexes have been extensively investigated for the delivery of nucleic acids, including DNA, siRNA, mRNA and other oligonucleotides. Their design aims to protect nucleic acids and facilitate cellular uptake and intracellular delivery.

Can polymeric nanoparticles be used in cancer research?

Yes. Polymeric nanoparticles are widely investigated in cancer research for drug delivery, imaging, combination therapies and stimulus-responsive nanomedicine. However, many applications remain experimental, and the effectiveness and safety of a particular nanoparticle must be demonstrated for its specific formulation and intended use.

What determines the properties of a polymeric nanoparticle?

Important parameters include polymer composition, particle size, size distribution, morphology, surface charge, surface chemistry, drug or biomolecule loading and formulation stability. These properties can influence interactions with biological systems and the release of the nanoparticle’s cargo.

What are the main challenges of polymeric nanoparticles?

Important challenges include controlling biodistribution and clearance, minimizing unwanted biological effects, achieving reproducible manufacturing at scale, ensuring long-term safety and translating promising laboratory results into clinically effective products.

Conclusion

Polymeric nanoparticles provide a flexible platform for designing nanoscale systems capable of carrying, protecting and releasing therapeutic or diagnostic molecules. Their tunable chemistry, potential biodegradability and ability to incorporate diverse cargo make them particularly attractive for biomolecule delivery, gene therapy, drug delivery and diagnostic applications.

At the same time, polymeric nanoparticles are not a universal solution: their biological behaviour depends strongly on their composition and formulation, and significant challenges remain before many experimental systems can reach routine clinical use.

Continued advances in polymer chemistry, nanoparticle synthesis, surface functionalization and biological characterization are helping researchers develop increasingly sophisticated systems. These developments are positioning polymeric nanoparticles as an important research platform within the broader field of nanomedicine and biomedical nanotechnology.

Related articles

  • …

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

• Read More